

In Barcelona, it being 4 p.m. on 9 November 2015, at the official address of the Josep Carreras Leukaemia Foundation under the presidency of Mr. Josep Carreras Coll and acting as secretary the holder of that post Mr. Calixto Mut Terrés-Camaló, the Board of the Josep Carreras International Foundation met with the personal attendance of the trustees listed below.

Present:

Mr. Josep Carreras i Coll

Prof. Evarist Feliu i Frasnado

Mr. Albert Carreras i Coll

Mr. Ramiro Giménez i Labrador.

Mr. Marcel Pascual i Forns

Mr. Arcadi Calzada i Salavedra

Mr. Albert Carreras i Pérez,

Dr. Alvaro Urbano i Izpizua

Prof. Jordi Sierra i Gil

Also attending:

Mr. Antoni García i Prat (Administrator)

Dr. Enric Carreras i Pons (REDMO Director)

Mr. Calixto Mut i Terrés-Camaló (Secretary of the Board and legal advisor)

With the justified absence of the following:

Dr. Rainer Storb - who delegated his vote to the President

Dr. Joan Uriach i Marsal - who delegated his vote to the President

Mr. Sr. Lluís Bassat i Coen - who delegated his vote to the President

Dr. Clarence Dean Buckner - who delegated his vote to the President

Mr. Joaquim Folch-Rusiñol

The meeting was duly convened in accordance with Articles 20 and 21 of the Foundation's Statutes with the following Agenda:

1. Reading and approval of the minutes of the previous meeting
2. Resignation from his post as Trustee of Mr. Rafael Jiménez de Parga
3. Approval, if applicable, of the Agreement with Hospital Clínic
4. Contribution to the capital increase of Leukos Biotech. S.L.

5. Money Laundering Prevention Manual update
6. Any further business

The meeting having begun, and declared validly constituted by the Chair, who greeted all those present, and after various deliberations, of which no record was requested in the Minutes, the following agreements were approved unanimously:

FIRST: Approval of the definitive version of the Minutes of the meetings of the Board of Trustees held on 22 April 2015, which had already been approved at the close of that meeting.

SECOND: The Secretary informed the members of the Board of the resignation of Prof. Rafael Jiménez de Parga Cabrera as a member of the Board of Trustees, after twenty-eight years of service to it, for personal reasons and on account of having insufficient time to attend to the Foundation's affairs. The President was informed of his decision by means of a letter signed and accepted by him on 21 June 2015.

It is with sorrow that the Board of Trustees acknowledges having been informed of the decision made by Prof. Jimenez de Parga and the Board expresses its gratitude for and approval of Mr. Parga's contribution as a member of the Board of Trustees. The Foundations Registry, where his resignation will be inscribed, will be duly informed.

THIRD: The Administrator, Mr. García Prat, informed the Board of the need to ratify, or if considered appropriate, to newly approve the agreement with Barcelona's Hospital Clínic, which was provisionally agreed and signed on 29 May 2015 by the President of the Foundation with the aim of jointly promoting scientific research, teaching and staff training in the field of endeavours to fight leukaemia and other malignant blood diseases. All those present had been issued with a copy of this agreement.

The Board, after various deliberations, of which no record was requested in the Minutes, ratified and, in in the event of it being necessary, newly approved the said agreement, it being emphasised that with the signing and implementation of the agreement funds were being devoted to the fulfilment of the foundational aims, in this case the promotion of scientific research to fight against leukaemia.

FOURTH: The Administrator, Mr. García Prat, informed the Board that it would be appropriate to subscribe the capital increase of the Leukos Biotech, S.L. company, a company that had been

set up by Dr. Ruth Muñoz Risueño and the Josep Carreras Leukaemia Research Institute Foundation to research, develop and market new drugs, treatments and diagnostic systems in the fight against leukaemia, something which would not entail the assumption of personal liability for company debt, with a contribution of up to ONE HUNDRED-THOUSAND EUROS (€100,000): SEVEN THOUSAND EUROS contribution to social capital and NINETY THREE THOUSAND EUROS as share premium. After this capital increase the Foundation would have a 70% holding in the company. It is expected that in future phases of the project funds may be raised from third parties entering as new partners who would similarly be obliged to pay a share premium, until the products which are the object of research and development are released on the market.

It was explicitly stated that this investment is directly ascribed to the foundational aims.

Given the information received from Mr. García Prat, and in accordance with the stipulations of Article 333-4 of the Civil Code of Catalonia, it was unanimously agreed to subscribe the capital increase of the Leukos Biotech, S.L. company, with a contribution of up to ONE HUNDRED-THOUSAND EUROS (€100,000): SEVEN THOUSAND EUROS contribution to social capital and NINETY THREE THOUSAND EUROS as share premium. The Foundation's Vice-president, Dr. Evarist Feliu Frasnado, was specifically authorised, with the powers he already enjoys, and if necessary with this specific authorisation, to formally implement this agreement, attend the Shareholders' General Meeting of the Leukos Biotech, S.L. company as the Foundation's representative and disburse the said capital increase, as well as, in the name of the Foundation, debate and vote on any other item on the meeting's Agenda, name and accept company posts, should such deliberations take place, and consequently to sign any private or public documents deemed necessary or appropriate, this authorisation being understood in the widest sense.

FIFTH: The updated version of the *Manual to Prevent Money Laundering*, presented by the Administrator, Mr. García Prat, was unanimously approved.

There being no further business to record in the Minutes, it being 5 p.m. the meeting was concluded and these Minutes approved by all those in attendance and signed by the Secretary and the President as proof of their approval.